(MYNZ - MAINZ BIOMED NV)

company profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.

Mainz Biomed N V (MYNZ) is trading at 0.9454

Open Price
1
Previous close
0.9454
Previous close
0.9454
P/E Ratio
0
Sector
Health Care
Shares outstanding
9060142
Primary exchange
NASDAQ-NMS
ISIN
NL0015000LC2